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ABSTRACT
The separation of embryonic from extra-embryonic tissues within the
inner cell mass to generate the epiblast (EPI), which will form the new
organism, from the primitive endoderm (PE), which will form the yolk
sac, is a crucial developmental decision. Here, we identify a chromatin
modifier, Satb1, with a distinct role in this decision. Satb1 is
differentially expressed within 16-cell-stage embryos, with higher
expression levels in the inner cell mass progenitor cells. Depleting
Satb1 increases the number of EPI cells at the expense of PE. This
phenotype can be rescued by simultaneous depletion of both Satb1
and Satb2, owing to their antagonistic effect on the pluripotency
regulator Nanog. Consequently, increasing Satb1 expression leads to
differentiation into PE and a decrease in EPI, as a result of the
modulation of expression of several pluripotency- and differentiation-
related genes by Satb1. Finally, we show that Satb1 is a downstream
target of the Fgf signalling pathway, linking chromatin modification
and Fgf signalling. Together, these results identify a role for Satb1 in
the lineage choice between pluripotency and differentiation and
further our understanding of early embryonic lineage segregation.
KEY WORDS: Satb1, Epiblast, Primitive endoderm, Cell lineage
specification, Preimplantation, Mouse
INTRODUCTION
The early mammalian embryo must correctly specify three distinct
cell lineages: the epiblast (EPI), which gives rise to the embryo
proper, and the two extraembryonic lineages, the trophectoderm
(TE) and the primitive endoderm (PE), which go on to form crucial
supportive structures, the placenta and the yolk sac, respectively. By
the 16-cell stage, the mouse embryo has a population of outside and
inside cells that follow different fates. The outside cells will give rise
to the TE, whereas the inside cells will form the pluripotent inner
cell mass (ICM) of the blastocyst. The PE and the EPI are both
derived from the ICM of the early blastocyst. Previous research has
shown that in the early blastocyst the ICM contains a mixed
population of PE and EPI progenitors in a mosaic ‘salt-and-pepper’
distribution, which sort themselves into distinct layers by the time
the blastocyst is ready to implant [embryonic day (E) 4.5)] through
active cell movements (Chazaud et al., 2006; Kurimoto et al., 2006;
Meilhac et al., 2009; Plusa et al., 2008). Even though they are a
mixed population early on, the individual cells in the early
blastocyst are distinct enough that they go on to form either PE or
EPI, but rarely both (Morris et al., 2010). It was shown that EPI
precursors expressing the pluripotency marker Nanog secrete Fgf4
ligand in the ICM, which can initiate a signalling cascade in Gata6-
positive PE precursors that have the Fgfr2 receptor highly expressed
on their membranes (Frankenberg et al., 2011; Kurimoto et al.,
2006; Morris et al., 2013; Ohnishi et al., 2014). This Fgf signalling
is crucial for preventing Nanog from inhibiting Gata6 and
committing cells to a PE cell fate (Frankenberg et al., 2011; Kang
et al., 2013; Krawchuk et al., 2013; Schrode et al., 2014). Indeed,
when Fgf signalling is inhibited, all ICM cells are directed towards a
Nanog-positive EPI cell fate without forming any PE, whereas
overexpression results in the opposite phenotype, with all cells
being converted into Gata6- and Sox17-positive PE (Chazaud et al.,
2006; Feldman et al., 1995; Frankenberg et al., 2011; Nichols et al.,
2009; Yamanaka et al., 2010). Although the role of Fgf signalling
has been well described in the embryo, much still remains unknown
about how the cell-fate choice between PE and EPI occurs. Our aim
was to contribute to the identification of new regulators of this
lineage decision process.
When we mined a pre-existing data set for genes differentially
expressed between the first precursors of ICM (inside cells) and TE
(outside cells) at the 16-cell stage (Graham et al., 2014), our
attention was drawn to Satb1, a chromatin modifier, which was three
times more highly expressed in inside cells compared with outside
cells, potentially indicating a role within the ICM. Although the role
of Satb1 in the early mouse embryo is unknown, it has been shown
to regulate pluripotency in mouse embryonic stem cells (mESCs;
Savarese et al., 2009), to regulate self-renewal and pluripotency in
both haematopoietic (Will et al., 2013) and trophoblast (Asanoma
et al., 2012) stem cells and to promote the differentiation of
haematopoietic stem cells (Satoh et al., 2013). Here, we wished to
test the hypothesis that Satb1 contributes to lineage specification
within the early mouse embryo.
RESULTS
Temporal and spatial expression of Satb1 in preimplantation
development
To investigate the potential role of Satb1 in early mouse embryos,
we first used qRT-PCR to analyse its expression throughout
preimplantation development. This revealed high levels of maternal
Satb1 mRNA at the zygote and two-cell stages, before the zygotic
genome is activated, a reduction in Satb1 at the four-cell stage
before expression increased at the eight-cell stage and was fairly
stable until the blastocyst stage (Fig. 1A). The presence of maternal
mRNA and the stable levels of expression after the eight-cell stage
prompted us to investigate Satb1 protein levels by
immunofluorescence. We found that the overall expression of
protein was highly similar to that of the mRNA, with maternal
protein present in the zygote and at the two-cell stage and a drop inReceived 25 August 2016; Accepted 3 March 2017
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Fig. 1. Satb1 expression throughout preimplantation development. (A) qRT-PCR of embryos at zygote (n=42), two-cell (n=43), four-cell (n=39), eight-cell
(n=41), 16-cell (n=41), E3.5 (n=54) and E4.5 (n=56) to investigate Satb1 mRNA levels. (B) Quantification of relative fluorescent intensity of Satb1 staining
throughout preimplantation development. Representative images are presented in C. (C) Immunofluorescence of Satb1 in zygote (n=14), two-cell (n=11), four-
cell (n=12), eight-cell (n=15), 16- to 32-cell (n=13) and E4.5 (n=16) embryos. (D) Scheme of isolation of inside and outside cells at the 16-cell stage for qRT-PCR
shown in E. (E) qRT-PCRof inside cells (n=35) and outside cells (n=41) from 16-cell stage embryos to investigateSatb1mRNA levels. (F) Immunofluorescence of
Satb1 in 16-cell embryos (n=13). Embryo boundary is outlined in white or black. Inside cells are indicated by yellow arrowheads. (G) Quantification of relative
fluorescent intensity of Satb1 staining. **P<0.01, ***P<0.001. Representative images are shown in F. Scale bars: 10 μm.
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expression by the four-cell stage (Fig. 1B,C). Protein levels
increased at the eight-cell (in a relatively homogenous fashion;
Fig. S1A,B) and 16-cell stages, with Satb1 protein still present until
the blastocyst stage in both the TE and ICM (Fig. 1B,C).
We first identified Satb1 as a gene of interest when examining our
earlier mRNA sequencing results (Graham et al., 2014) that
revealed it to be three times more highly expressed in inside cells
compared with outside cells at the 16-cell stage. To confirm this
expression pattern, we determined Satb1mRNA levels in inside and
outside cells using qRT-PCR. To isolate the individual populations
of inside or outside cells, we labelled 16-cell stage embryos by
briefly incubating them in a suspension of 0.2 µm fluorescent beads
and then segregating inside and outside cells by gentle pipetting, as
has been done previously (Graham et al., 2014). Separated
individual outside (fluorescent) and inside (non-fluorescent) cells
were pooled together for mRNA extraction (Fig. 1D). In total, 35
inside cells and 41 outside cells (over three experiments) were
collected. Inside cells were found to have over 3.5 times more Satb1
mRNA than outside cells (Fig. 1E; P<0.001).
Given that Satb1 protein expression peaked at the 16-cell stage,
we next investigated whether the differential expression of Satb1
mRNA at the 16-cell stage is recapitulated at the protein level.
Fluorescence intensity measurements of Satb1 staining for outside
cells (those that had at least one domain in contact with the outside
of the embryo) were compared with the intensity of inside cells
(cells that were entirely surrounded by other cells) relative to 4′,6-
diamidino-2-phenylindole (DAPI). Intensity measurements were
done on the layer-normalized sections using the ImageJ measure
function. We found that inside cells had more than twofold more
Satb1 protein than the outside cells (Fig. 1F,G). These results
indicate that at both protein andmRNA levels, Satb1 is differentially
expressed at the 16-cell stage.
Depletion of Satb1 increases number of pluripotent cells
To determine whether Satb1 might play any role in the
preimplantation embryo, we next decreased its expression using a
combination of three Satb1-specific small interfering RNAs
(siRNAs). We first confirmed that these siRNAs reduced Satb1 at
both the mRNA and protein level despite the prevalence of maternal
protein and mRNA (Fig. 2A,B) and that the reduction in Satb1
protein persisted until the blastocyst stage (Fig. S1C,D). To test the
effect of Satb1 knockdown, we injected zygotes with Satb1 siRNA
and cultured embryos until the blastocyst stage to compare the cell
lineage allocation to embryos injected with a control siRNA
(Fig. 2C). We found that Satb1 RNA interference (RNAi)
blastocysts had a severely reduced number of PE cells as assessed
by Sox17 expression (Fig. 2D,E, Fig. S2). The total number of cells
(average of 105 in control and 103 in Satb1 siRNA blastocysts) as
well as the number of TE cells (Cdx2+ cells; average of 86 in control
and 83 in Satb1 siRNA) did not change after Satb1RNAi (Fig. 2D,E).
Importantly, we found that the 38% reduction in PE cells was met
with a 47% increase in EPI cells as assessed by the expression of
Nanog and Sox17 (Fig. 2D,E), suggesting that reduced levels of
Satb1 bias the ICM to produce more EPI rather than PE. To confirm
this result, we next injected each Satb1 siRNA individually. We
observed the same developmental defect using individual siRNAs
as noted with the combination of Satb1 siRNAs, with a reduction in
PE cells and an increase in EPI cells (Fig. S1E,F). This phenotype
was also found to be proportional to the efficacy of Satb1
knockdown (Fig. S1G), indicating that the bias in cell fate
observed upon Satb1 depletion is specific to decreased Satb1 and
not attributable to off-target effects. We validated these findings by
assessing the expression of two additional PE markers, Gata6 and
Pdgfra, as well as an additional EPI marker, Sox2, after Satb1
RNAi, and found a similar bias, with Satb1-reduced embryos
having an increase in EPI and a decrease in PE by the blastocyst
stage (Fig. S3). We next investigated the timing of the effect of
Satb1 RNAi in the embryo. We found that at the 16-cell stage
(Fig. S4A,B) and at the initiation of the blastocyst, the 32-cell stage
(Fig. S4C,D), there was no effect on the distribution or expression
pattern of Gata6 or Nanog after Satb1 RNAi. However, by the
early blastocyst stage we noted a significant reduction in the
number of cells expressing Gata6 after Satb1 RNAi (Fig. S4E,F).
These data suggest that although Satb1 has no effect on the initiation
of PE specification, it does have a specific role in PE lineage
commitment.
The reduction in PE and increase in EPI after Satb1 RNAi
suggested that Satb1 could have a role in the cell-fate choice within
the ICM. To verify this result, we next determined whether
individual blastomeres with reduced Satb1 could have a preferential
fate. To this end, we injected one blastomere of two-cell stage
embryos with Satb1 or control siRNA, together with the membrane-
bound phosphoprotein Gap43-GFP (Benowitz and Routtenberg,
1987) mRNA, which can serve as a marker of cell lineage by
labelling the membranes of injected cells (Fig. 2F). The embryos
were cultured for 72 h, until the late blastocyst stage, and the
contribution to TE, EPI and PE was scored by assessing molecular
markers for each lineage and cell position within the embryo. In
comparison with control-injected embryos, we found that Satb1
siRNA-injected blastomeres contributed significantly more to the
EPI (Fig. 2G,H; P<0.001). Consequently, Satb1 siRNA-injected
blastomeres also contributed significantly fewer cells to the PE
(Fig. 2G,H; P<0.001; cells contributed to the PE: 4.96 in control
embryos, 2.28 in Satb1 RNAi embryos). In agreement with previous
results, injection of Satb1 siRNA into half of the embryo had no
effect on the relative total contribution of injected cells or the
contribution to the TE when compared with control-injected
embryos (Fig. 2G,H). These results indicate that clonal depletion
of Satb1 biases cell-fate choice in the embryo: cells with lower
Satb1 will preferentially give rise to the EPI as opposed to the PE.
Increasing Satb1 decreases the number of pluripotent cells
Given that reducing Satb1 directs cells towards the pluripotent
lineage, we hypothesized that Satb1 might have a role in promoting
a PE lineage. To investigate the expression pattern of Satb1 in
presumptive PE and EPI cells, we analysed Satb1 expression,
together with Gata6 (a marker of PE progenitors), in the blastocyst
ICM.We found that Satb1 expression was significantly higher in PE
precursors as opposed to EPI precursors (Fig. 3A,B; P<0.001), as
would be expected of a gene with a role in PE specification. To
investigate whether overexpressing Satb1 might have the opposite
effect to its reduction, we reverse transcribed mRNA from a Satb1
cDNA, injected it into zygotes (400 ng/μl) and let embryos develop
until morula stage, when we analysed them by qRT-PCR. We found
that the injection of Satb1 mRNA resulted in a more than twofold
increase in Satb1 mRNA levels (Fig. 3C; P<0.05), indicating that
overexpressing Satb1 is effective. To test whether overexpressing
Satb1 mRNA was able to rescue the phenotype seen after Satb1
siRNA, we depleted Satb1 siRNA in the zygote and then
overexpressed Satb1 mRNA in both blastomeres of the two-cell
stage embryo (Fig. S5A). Overexpression of Satb1 was able to
return the number of PE and EPI cells to levels similar to controls,
providing evidence for the specificity of the siRNA phenotype
(Fig. S5B,C).
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To test the consequences of increasing Satb1 mRNA on lineage
allocation, we first injected Satb1 mRNA into zygotes and allowed
them to develop until the blastocyst stage and compared the
contribution of mRNA-injected embryos to TE, EPI and PE
(Fig. 3D). Overexpression of Satb1 resulted in a significant increase
in the number of PE cells (P<0.01) and a significant decrease in the
Fig. 2. See next page for legend.
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number of EPI cells (P<0.01) when compared with controls
(Fig. 3E,F), the opposite effect of what we found when knocking
down Satb1. These results indicate that modulating the levels of
Satb1 has a specific effect on the differentiation of the ICM into PE
or EPI: an increase in Satb1 levels pushes ICM cells preferentially to
form PE instead of EPI.
To verify this result, we also determined the lineage contribution
when increasing Satb1 clonally. To this end, we injected 400 ng/μl
of Satb1 mRNA together with Gap43-GFP mRNA into one
blastomere of a two-cell embryo, cultured the embryos to the
blastocyst stage and assessed lineage contribution using molecular
markers as well as cell position (Fig. 3G). We found that Satb1
mRNA injection resulted in a significant decrease in contribution to
the EPI (Fig. 3H,I; P<0.05; cells contributed to the EPI: 5.16 in
control embryos, 3.61 in Satb1 RNAi embryos) as well as a
significant increase in PE contribution relative to control (Fig. 3H,I).
These results were not attribuatble to a reduction in total or TE cell
contributions, as both Satb1 mRNA and control mRNA embryos
were similar in their TE and total number of cells (Fig. 3H,I).
Therefore, clonal overexpression of Satb1 biases ICM cells to form
PE and not EPI. Collectively, these results, together with the clonal
siRNA results, indicate that modulating the amount of Satb1 in the
embryo has a specific effect on cell-fate choice within the ICM.
Simultaneous depletion of Satb1 and Satb2 rescues Satb1
depletion
Satb2 is closely related to Satb1, and it has been shown that
knocking down both Satb1 and Satb2 simultaneously in mESCs can
rescue the impaired differentiation noted in Satb1−/− mESCs
(Savarese et al., 2009). We therefore decided to investigate whether
Satb2 RNAi could also rescue the Satb1 siRNA phenotype in the
embryo. We first tested the effectiveness of Satb2 siRNA using
qRT-PCR. To this end, Satb1 siRNA, Satb2 siRNA or a
combination of both was injected into zygotes at a final total
concentration of 12 μM and embryos were collected at the 16-cell
stage for mRNA extraction. We found that the knockdown of Satb2
siRNA did not affect Satb1 mRNA levels but was effective in
reducing Satb2 mRNA by 63% when compared with control
(Fig. 4A; P<0.01). Interestingly, Satb1 RNAi resulted in a more
than twofold increase in Satb2mRNAwhile reducing Satb1mRNA
by almost 70% (Fig. 4A; P<0.001). The opposite result was found
when Satb1 was overexpressed, with a 50% reduction in Satb2
mRNA along with a twofold increase in Satb1 mRNA (Fig. S6;
P<0.05). These results show that RNAi for both of these closely
related genes is specific to each gene and that Satb1 might be a
negative regulator of Satb2. Additionally, double knockdown of
Satb1 and Satb2 reduced the levels of both mRNAs to ∼40% of the
control values (Fig. 4A; P<0.01), indicating that the siRNAs can
work simultaneously without interfering with one another when
injected into the same embryos.
We next determined the effect of Satb2 siRNA on lineage
specification and whether or not it could rescue the Satb1 siRNA
phenotype. To this end, Satb1 siRNA, Satb2 siRNA or a combination
of both were injected into zygotes at a final total concentration of
12 μM and embryos were allowed to develop until E4.5, when their
lineage specification was evaluated (Fig. 4B). We found that Satb2
siRNA by itself had no effect on preimplantation development, with a
similar number of TE, PE and EPI cells present compared with
controls (Fig. 4C,D).However, double knockdownofSatb1 andSatb2
siRNA was able to rescue the Satb1 siRNA phenotype significantly,
leading to the number of EPI and PE cells being more similar to
control embyros (Fig. 4C,D). These results indicate that Satb2 and
Satb1 have antagonistic effects on cell-fate choice within the ICM.
Satb1 modulates the expression of cell-fate regulators
As our results indicate that modulating the levels of Satb1, and to a
lesser degree Satb2, affects the cell-fate choice within the ICM, we
next wished to determine the changes in gene expression as a result
of changing the levels of Satb1 and Satb2, concentrating on key cell-
fate determinants at this stage. To this end, we injected Satb1
siRNA, Satb1 mRNA, Satb2 siRNA or Satb2 mRNA into zygotes
and allowed them to develop until the morula stage (about the 32-
cell stage) before mRNA extraction (Fig. 5A,B). We found that
Satb1 RNAi resulted in a significant increase in the key EPI
regulators Nanog, Oct4 and Sox2 (Fig. 5A; 3.9-, 2.5- and 1.98-fold,
respectively; Nanog and Oct4: P<0.001; Sox2: P<0.01). It also
resulted in a significant decrease in the differentiation markers of the
TE, such as Cdx2 (P<0.05) and Id2 (P<0.001), and also PE marker
genes, such as Gata6 (P<0.01) and Sox17 (P<0.01). As expected,
injection of Satb1mRNA had the opposite effect, with a decrease in
Nanog and increases in Id2, Gata6 and Sox17 expression (Fig. 5A;
Nanog: P<0.05; Id2, Gata6 and Sox17: P<0.001). Satb2 RNAi also
resulted in decreased expression ofNanog (Fig. 5B; P<0.05) but did
not alter the expression of any of the other genes examined here
(Fig. 5B), perhaps accounting for the lack of a phenotype noted after
Satb2 RNAi. Interestingly, overexpression of Satb2 resulted in an
almost twofold increase in Nanog, Oct4 and Sox2 without affecting
the other lineage markers (Fig. 5B; Nanog and Sox2: P<0.05; Oct4:
P<0.01), indicating a potential role in promoting an EPI lineage. In
agreement with this, we found Satb2 to be co-expressed with Nanog
in the early blastocyst and, consequently, to be significantly more
highly expressed in EPI cells as opposed to PE cells by the late
blastocyst (Fig. S7A,A′,B; P<0.001). Overall, these results indicate
that Satb1 modulates the expression of cell-fate regulators during
preimplantation development and that Satb1 and Satb2 have
antagonistic effects on Nanog expression within the early embryo.
Fgf signalling regulates Satb1
As the above results indicated that Satb1 is involved in the
specification of PE and EPI in the ICM, we next wished to
Fig. 2. Reducing Satb1 biases ICM cell fate towards EPI over PE. (A) qRT-
PCR of embryos injected with control siRNA (n=52 embryos, three biological
repeats) and Satb1 siRNA (n=61 embryos, three biological repeats) to
investigate Satb1mRNA levels. Embryos were injected at zygote and isolated
at the eight-cell stage. Embryos injected with Satb1 siRNA show a reduction in
Satb1 mRNA by the eight-cell stage. (B) Immunofluorescence of Satb1 in
eight-cell embryos after being injected with control (n=11) or Satb1 siRNA
(n=15). (C) Scheme of Satb1 siRNA experiment shown in D and E. Zygotes
were injected with Satb1 siRNA or control siRNA and cultured until E4.5.
(D) Contribution of control (n=29) andSatb1 (n=36) siRNA-injected embryos to
EPI, PE and TE. Representative images of the experiment are shown in E,
(E) Confocal images of control and Satb1 siRNA-injected embryos. Nanog,
(EPI), Sox17 (PE) and Cdx2 (TE) were used as lineage markers (related to
Fig. S2). (F) Scheme of clonal Satb1 siRNA experiment shown in G andH.One
blastomere of two-cell stage embryos was injected with Satb1 siRNA, or
control siRNA, and Gap43-GFP mRNA. Embryos were cultured to the late
blastocyst stage, and the contribution of the injected cells’ progeny to each
lineage was analysed. (G) Confocal images of control (n=21, average of 5.2
Sox17-positive/Gap43-GFP-negative and an average of 4.96 Sox17-positive
/Gap43-GFP-positive blastomeres per embryo) and Satb1 (n=29, average of
7.84 Sox17-positive/Gap43-GFP-negative and an average of 2.28 Sox17-
positive/Gap43-GFP-positive blastomeres per embryo) siRNA-injected
embryos. Sox17 (PE) and Cdx2 (TE) were used as lineage markers. Asterisks
indicate ICM cells contributed from injected blastomeres. (H) Contribution of
Satb1 siRNA-injected cells from experiment shown in G to TE, PE and EPI,
relative to control siRNA-injected cells. ***P<0.001. Scale bars: 10 μm.
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Fig. 3. See next page for legend.
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determine the upstream regulator of Satb1. It was shown that the
inhibition of Fgf signalling influenced the dependence of mESCs on
Satb1 (Savarese et al., 2009). This is particularly interesting because
Fgf signalling is crucial to PE fate specification (Frankenberg et al.,
2011; Kang et al., 2013; Morris et al., 2013; Yamanaka et al., 2010).
To determine whether inhibition of the Fgf signalling pathway
affects Satb1 expression in the early mouse embryo, we determined
the effects of two different Fgf signalling pathway inhibitors on
Satb1 expression. We used an Fgf receptor inhibitor (Morris et al.,
2013; Nichols et al., 2009; Yamanaka et al., 2010) and a Mek
inhibitor (Nichols et al., 2009; Schrode et al., 2014; Yamanaka
et al., 2010) because they are well documented to block PE
formation in the embryo.We treated two-cell stage embryos with the
Fgf receptor inhibitor at a concentration of 100 nM (Morris et al.,
2012) and the Mek inhibitor at a concentration of 0.5 μM
(Yamanaka et al., 2010) and then allowed the embryos to develop
until the eight-cell stage, when they were fixed and immunostained
for Satb1 (Fig. 6A). We found that embryos treated with either
inhibitor showed a significant decrease in Satb1 protein by the eight-
cell stage (Fig. 6B,C; P<0.001).
To examine whether the reduction in Satb1 levels after Fgf
inhibition could be rescued by the addition of exogenous Satb1
mRNA, we injected Satb1mRNA into embryos at the two-cell stage
and then treated them with inhibitors until the eight-cell stage
(Fig. 6A). In these embryos, Satb1 was returned to similar levels as
in controls (Fig. 6B,D). These results suggest that Fgf signalling is
involved in the regulation of Satb1 in the preimplantation mouse
embryo.
DISCUSSION
The specification of three distinct cell lineages in the mouse
embryo occurs during two cell-fate decisions. The first cell-fate
decision physically separates the population of ICM and TE cells,
Fig. 3. Effect of Satb1 overexpression on preimplantation development.
(A) Confocal images of Satb1 staining in early blastocysts (n=19). Gata6 (PE)
and Cdx2 (TE) were used as lineage markers. Yellow arrowheads indicate PE
precursors. White asterisks indicate EPI precursors. (B) Quantification of
relative fluorescent intensity of Satb1 staining fromA. (C) qRT-PCRof embryos
injected with control mRNA (n=42 embryos) orSatb1mRNA (n=54 embryos) to
investigate Satb1 mRNA levels. (D) Scheme of Satb1 overexpression
experiment shown in E and F. Zygotes were injected with Satb1 or control
mRNA and cultured until E4.5. (E) Contribution of cells injected with Satb1
mRNA (n=23) to TE, PE and EPI, relative to cells injected with control mRNA
(n=25). Representative images of the experiment are shown in F. (F) Confocal
images of control and Satb1 mRNA-injected embryos. Nanog (EPI), Sox17
(PE) and Cdx2 (TE) were used as lineage markers. (G) Scheme of clonal
Satb1 mRNA experiment shown in H and I. One blastomere of two-cell stage
embryos was injected with Satb1 mRNA and Gap43-GFP mRNA. Embryos
were cultured to the late blastocyst stage, and the contribution of the injected
cell’s progeny to each lineage was analysed. (H) Confocal images of embryos
injected with control (n=19, average of 5.32 Nanog-positive/Gap43-GFP-
negative and an average of 5.16 Nanog-positive/Gap43-GFP-positive
blastomeres per embryo) and Satb1 mRNA (n=26, average of 7.27 Nanog-
positive/Gap43-GFP-negative and an average of 3.61 Nanog-positive/Gap43-
GFP-positive blastomeres per embryo). Sox17 (PE) and Nanog (EPI) were
used as lineage markers. White arrowheads indicate ICM cells contributed
from injected blastomeres. (I) Contribution of Satb1 mRNA-injected cells from
experiment shown in H to TE, PE and EPI, relative to control mRNA-injected
cells. *P<0.05, **P<0.01, ***P<0.001. Scale bars: 10 μm.
Fig. 4. Rescue of Satb1 siRNA phenotype by Satb2 siRNA. (A) qRT-PCR of embryos injected with control (n=39 embryos), Satb1 (n=52 embryos), Satb2
(n=64 embryos) or Satb1+Satb2 (n=52 embryos) siRNA to investigate Satb1 mRNA levels. (B) Scheme of Satb1 and Satb1 siRNA experiment shown in C and
D. Zygotes were injected with Satb1 siRNA and/or Satb2 siRNA and cultured until E4.5. (C) Contribution of cells injected with Satb1 (n=16), Satb2 (n=29) and
Satb1+Satb2 (n=32) siRNA to TE, PE and EPI, relative to control [control numbers were normalized to 100, to allow comparison with experimental siRNA-injected
embryos (n=13) (not shown)]. Representative images of the experiment are shown in D. (D) Confocal images of embryos injected with control, Satb1, Satb and
Satb1+Satb2 siRNA. Nanog (EPI), Sox17 (PE) and Cdx2 (TE) were used as lineage markers. *P<0.05, **P<0.01, ***P<0.001. Scale bar: 10 μm.
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whereas the second cell-fate decision further specifies the ICM
into the PE and the EPI. It is critical that all three lineages are
correctly specified in order to form a blastocyst capable of
implanting into the uterine wall and developing further. Here,
aiming to identify new regulators that control cell-fate choice in
preimplantation development, we discovered the chromatin
modifier Satb1 as an important player. Satb1 was first identified
in thymocytes, where it is known to regulate gene expression by
organizing the structure of higher-order chromatin into loop
domains and by acting as a ‘landing platform’ for chromatin-
remodelling enzymes (Cai et al., 2006; Yasui et al., 2002). In
mESCs, Satb1 was shown to regulate pluripotency by directly
repressing Nanog; Satb1 knockout mESCs maintained Nanog
expression even when placed into differentiation medium
(Savarese et al., 2009). However, the role of Satb1 in the
preimplantation embryo remains unknown. Here, we find that
expression of Satb1 is specifically upregulated, at both mRNA and
protein levels, in the inner cells of 16-cell stage embryos, when
the ICM is first specified, indicating a potential role within the
specification of these cells. We further find that Satb1 is
specifically upregulated within the PE precursors, signifying its
potential importance to the specification of the PE. We confirm
this hypothesis by downregulating Satb1, which we show leads to
a reduction in the number of PE cells and an increase in the
number of EPI cells by the blastocyst stage. In agreement with
this, overexpression of Satb1 has an opposite effect on lineage
specification and promotes a PE lineage within the ICM. Our
clonal knockdown and overexpression experiments further support
these findings as we find that blastomeres with reduced Satb1
preferentially give rise to EPI and those with increased Satb1
preferentially give rise to PE. We find that Satb1 does not have an
effect on the 16- to 32-cell stage embryo when PE specification is
initiated. Rather, it has a role in the commitment of cells within
the blastocyst to the PE lineage. We also find that this change in
cell fate is attributable to modulation of the expression of a series
of lineage-specific genes downstream of Fgf signalling.
We find that although modulating Satb1 expression clearly
affects cell-fate commitment in the preimplantation mouse embryo,
it rarely results in a complete ablation of either the PE or EPI
lineages. This is important when viewed in context of the Satb1
knockout mice, which survive during embryogenesis but die by 3
weeks of age (Alvarez et al., 2000). If Satb1 is important for the
regulation of a balance between pluripotency and differentiation as
has been shown here, how can this be reconciled with the lack of a
preimplantation phenotype in knockout mice? It has previously
been shown that the minimal requirement for successful
development is three to four pluripotent cells by the time of
implantation (Morris et al., 2012; Soriano and Jaenisch, 1986). If
Satb1−/− embryos did have a phenotype, based on the results from
this study, they would most probably have an ICM with high
numbers of EPI cells and low numbers of PE cells. Similar
phenotypes have been found in Fgf4+/− and Gata6+/− embryos, and
in both cases, embryos were able to recover by E4.5 (Bessonnard
et al., 2014; Krawchuk et al., 2013). Therefore, it is possible that
although Satb1 helps to organize and specify the correct number of
PE and EPI cells within the ICM, it might not be absolutely essential
for embryo survival and can be compensated for, in agreement with
the highly regulative nature of mammalian development.
Satb1 is closely related to another family member, Satb2, leading
us to investigate whether Satb2 might also have a function in
preimplantation development. We find that although
downregulating Satb2 by itself has no effect on development,
depletion of both genes at once is partly able to rescue the Satb1
RNAi phenotype. This is in agreement with the results in mESCs,
because knockdown of both Satb1 and Satb2 rescued the disruption
in differentiation noted in Satb1−/− mESCs (Savarese et al., 2009).
Our results indicate that this is likely to be because knocking down
Satb2 reduces NanogmRNA, the opposite effect to reducing Satb1.
Fig. 5. Gene expression changes after modulation of Satb1 and Satb2. (A) qRT-PCR of various genes in embryos injected with control siRNA (n=59
embryos), Satb1 siRNA (n=62 embryos) orSatb1mRNA (n=71 embryos). (B) qRT-PCRof various genes in embryos injected with control siRNA (n=59 embryos),
Satb2 siRNA (n=73 embryos) or Satb2mRNA (n=58 embryos). In all instances, zygotes were injected and cultured until morula. *P<0.05, **P<0.01, ***P<0.001.
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In agreement with this, overexpression of Satb2 is able to increase
Nanog expression, providing evidence that Satb2 is a positive
regulator of Nanog. Satb1 and Satb2 therefore have antagonistic
effects onNanog expression. Thus, we hypothesize that when Satb1
alone is reduced it releases its repression on both Nanog and Satb2,
and this is enough to bias cell-fate choice towards the EPI. This bias
is strengthened by the fact that Satb1 also acts as a positive regulator
of PE differentiation factors Sox17 and Gata6. Knocking down both
Satb1 and Satb2 removes both the repression and activation of
Nanog expression, with the net effect of normalizing Nanog
expression levels. The results we present here showing the effect of
Satb2 onNanogmight help to explain why it has been impossible to
derive Satb2−/− mESCs (Savarese et al., 2009), because without
appropriate expression level of Nanog, it would be impossible to
derive functional ESC clones.
The effect of Satb2 on Nanog expression raises the question of
why reducing Satb2 levels in the embryo did not affect development
to the same degree as modulation of Satb1. One explanation is that
although Satb2 siRNA was able to reduce Nanog levels, more than
65% of Nanog mRNA was still present after RNAi. Although
Nanog is a crucial factor in determining cell fate, in the highly
regulative mouse embryo a 35% reduction in Nanog levels might
not be sufficient to drive cell-fate changes. Additionally, our results
suggest that although Satb2 might affect only Nanog expression in
embryos, Satb1 has effects on the expression of multiple genes,
including Cdx2, Gata6, Id2 and Sox17. The same pattern, albeit
with the opposite effects on expression, was noted for
overexpression of Satb1 and Satb2. The combined effects of
Satb1, on numerous genes, are sufficient to drive cell-fate changes
within the ICM. Modulating Satb2, however, only moderately
affects Nanog. This can also explain why the double knockdown of
Satb1 and Satb2 results in only a partial rescue of the Satb1 siRNA
phenotype, because although Nanog expression levels might be
saved, the effects on the other genes regulated by Satb1 are not.
Finally, our results indicate that Satb1 expression is controlled by
Fgf signalling, as we find that inhibition of Fgf signalling inhibits
Satb1 expression, which can be restored by the addition of
exogenous Satb1 mRNA. We also attempted to rescue the
perturbation in cell fate that is noted after Fgf signalling inhibition
(Nichols et al., 2009; Schrode et al., 2014; Yamanaka et al., 2010)
by overexpressing Satb1 mRNA but were unable to restore the
expression of PE markers by the blastocyst stage (data not shown).
We predict that this is because the Fgf signalling pathway has awide
variety of targets in the mouse embryo, and so rescuing one
Fig. 6. The effect of Fgf signalling on Satb1 expression. (A) Scheme of Fgf inhibition experiments in B-D. Two-cell stage embryos were either injected
withSatb1mRNA orRubymRNA and treated with a Fgf signalling inhibitor or left untreated before isolation at the eight-cell stage for analysis. (B) Quantification of
relative fluorescent intensity of Satb1 staining from C and D. (C) Confocal images of control embryos (n=18) and embryos treated with Mek inhibitor (n=20),
or Fgfr2 inhibitor (n=22). (D) Confocal images of control embryos (n=18), embryos treated with Mek inhibitor and injected with Satb1mRNA (n=17) and embryos
treated with Fgfr2 inhibitor treated and injected with Satb1 mRNA (n=15). **P<0.01. Scale bars: 10 μm.
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downstream pathway is not sufficient to overcome the multiple
effects of inhibiting Fgf signalling. In agreement, repression of Fgf
signalling results in a similar but much stronger phenotype
compared with downregulation of Satb1, with all ICM cells
expressing EPI lineage markers (Frankenberg et al., 2011;
Yamanaka et al., 2010). This indicates that Satb1 might be one of
the links between Fgf signalling and its downstream targets in early
mouse embryos. In agreement with this, Fgf signalling and Satb1
both promote stem cell maintenance and proliferation and inhibit
differentiation of trophoblast stem cells (Asanoma et al., 2012;
Tanaka et al., 1998).
Taken together, our results suggest that Satb1 might act as a
chromatin modifier, modulating gene expression downstream of Fgf
signalling, pointing to a crucial missing step of chromatin
remodelling that can serve to establish the progenitors of the two
distinct lineages within the ICM. We speculate that Satb1 could
potentially act in two manners to direct ICM cell fate. Firstly,
as Satb1 has been found, through co-immunoprecipitation
experiments, to bind directly to the 5′ flanking sequence of Nanog
in mESCs (Savarese et al., 2009), we predict that Satb1 would also
bind directly upstream of Nanog to repress its transcription in mouse
embryos. Secondly, as we find that Satb1 can regulate the expression
of numerous genes in the mouse embryo, we predict that this is a
function of its ability to act as a ‘landing platform’ that is able to
recruit chromatin-remodelling enzymes to activate or repress gene
expression, as has been shown previously (Yasui et al., 2002).
In conclusion, it can be hypothesized that cells within the ICM
have different levels of Fgf receptor, Fgfr2, on their membranes, as
has been previously shown (Guo et al., 2010; Krupa et al., 2014;
Kurimoto et al., 2006; Morris et al., 2013; Ohnishi et al., 2014).
Cells with more receptor are more susceptible to Fgf ligand (which
is secreted by the inside cells at this stage) and thus have higher
levels of Satb1 (Fig. 7). Higher expression of Satb1 would lead to
the inhibition of the pluripotency factors Nanog and Satb2, which in
turn would lead them to initiate differentiation into the PE lineage
(Fig. 7). Cells that are less susceptible to Fgf4 signalling will have
reduced Satb1 which, in turn, leads to more Nanog expression and
therefore biases cell fate towards the pluripotent EPI lineage.
Additionally, loss of both Satb1 and Satb2 removes both an
activator and repressor of Nanog, resulting in the formation of a
normal ICM (Fig. 7). This hypothesis, based on the results we
present here, helps to further our understanding of the mechanism
that leads to resolution of the ‘salt-and-pepper’ distribution of
Gata6- and Nanog-expressing progenitors within the ICM.
MATERIALS AND METHODS
Collection of mouse embryos
Embryo recovery was done on superovulated F1 (C57Bl/6xCBA) females
between 4 and 6 weeks old, as has been described previously (Piotrowska
et al., 2001). Following collection or experimental manipulation, embryos
were cultured in drops of potassium-supplemented simplex optimisedmedium
(KSOM;Millipore) supplementedwith 4 mg/ml bovine serum albumin under
paraffin oil at 37.5°C in air enriched with 5% CO2.
Collection of individual cells
Individual cells for qRT-PCR were collected at the 16-cell stage (78 h after
human chorionic gonadotrophin), as has been done previously (Graham
et al., 2014). Embryos were isolated directly at the 16-cell stage and
incubated in M2 with a fluorescently labelled 0.2 mm microsphere
suspension (Polysciences, Inc.) diluted to 1:50 for 30 s. Outside (strongly
fluorescent) and inside (non-fluorescent) cells were collected, grouped and
placed into Arcturus Biosciences PicoPure RNA isolation kit extraction
buffer for mRNA isolation.
Treatment with chemical inhibitors
To inhibit Fgf signalling, embryos were treated from the zygote to eight-
cell stage with an Fgf receptor inhibitor at a concentration of 100 nM
Fig. 7. Model for the role of Satb1 in ICM lineage segregation. A ‘salt-and-pepper’ distribution of Fgfr2 by the 64-cell stage means that different cells have
different responses to Fgf4 signalling. Cells with lower levels of Fgfr2 are less susceptible to Fgf4 signalling and do not upregulate Satb1. Nanog is therefore
more highly expressed, promoting the formation of EPI. When Satb1 is knocked down using a specific siRNA there is an increase in Nanog and therefore an
increase in the number of EPI cells present in the embryo. Conversely, cells that are more susceptible to Fgf4 signalling have higher levels of Satb1. Higher
expression of Satb1 leads to the inhibition of Nanog and Satb2. This in turn leads these cells to differentiate into PE. Overexpression of Satb1 with an mRNA is
likewise able to bias cell fate towards the PE lineage. Reducing both Satb1 and Satb1 simultaneously is able to restore the balance in PE and EPI by removing
both an activator and repressor of Nanog.
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(Stemgent; PD173074) or a Mek inhibitor (Stemgent; PD0325901) at a
concentration of 0.5 μM, both in KSOM. Inhibitors were dissolved in
dimethyl sulphoxide (DMSO; final concentration of DMSO was 0.005%).
Control embryos were incubated in the equivalent DMSO concentration but
in the absence of the inhibitor. Following treatment with inhibitors, embryos
were fixed and processed for immunostaining.
Microinjection of siRNAs and mRNAs
All microinjections were done with siRNAs for Satb1 and Satb2 as well as
AllStars Negative Control siRNA purchased from Qiagen. For siRNA
sequences, see Supplementary Materials and Methods. Satb1 and Satb2
cDNA (Dharmacon) was cloned into pRN3P as described previously
(Zernicka-Goetz et al., 1997). In vitro transcription was undertaken on
linearized cDNA using the mMessage mMachine T3 kit (Ambion)
according to the manufacturer’s instructions. Microinjection of embryos
with siRNA (always at a final concentration of 12 μM) or mRNA [together
with Ruby mRNA (200 ng/μl) or Gap43-GFP mRNA (400 ng/μl) as
markers of injection] was carried out in M2 covered in oil on a glass
depression slide using a Femtojet micro-injection system (Eppendorf ).
Embryos were cultured in KSOM under paraffin oil at 37.5°C in air enriched
with 5% CO2.
Immunofluorescence
Immunofluorescence was carried out as described previously
(Jedrusik et al., 2008). Multichannel imaging was acquired on a
Leica SP5 inverted confocal microscope using Leica LAS AF software
and a 20× or 40× oil immersion objective. Confocal z-stacks were
exported to ImageJ for image processing, intensity measurements and cell
counting. For details of the immunofluorescence protocol and intensity
measurements as well as antibody details, see supplementary Materials and
Methods.
qRT-PCR
qRT-PCR was carried out as previously described (Goolam et al., 2016).
Gapdh orH2afzwas used as the endogenous control.H2A.Zwas used when
different stages of preimplantation development were compared. Three
biological repeats were undertaken for every qRT-PCR. For primer details,
see supplementary Materials and Methods.
Statistical analyses
Unless otherwise specified, Student’s unpaired t-tests were used to test
significance (*P<0.05, **P<0.01, ***P<0.001). All error bars represent s.e.m.
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